CLL Coverage from Every Angle

William G. Wierda, MD, PhD, on Using Venetoclax in CLL

Posted: Monday, August 5, 2019

What steps do you take to prevent tumor-lysis syndrome associated with targeted agents in CLL such as idelalisib, ibrutinib, and venetoclax?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.